俄亥俄州 的 急性髓系白血病 临床试验
俄亥俄州 有 56 项针对 急性髓系白血病 的研究正在招募参与者。
俄亥俄州 的城市
官方研究文本（英文）
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月12日 · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 至 59 岁 · 所有性别 · 更新于 2026年11月9日 · NCT05554406Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月9日 · NCT06930352HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
招募中观察性研究
12 至 80 岁 · 所有性别 · 更新于 2026年11月6日 · NCT07145411Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Cincinnati OH-CINCY, Cincinnati
- US-Colombus OH-OSU, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月6日 · NCT07223814Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
60 岁及以上 · 所有性别 · 更新于 2026年11月6日 · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- 以及另外 44 项
招募中观察性研究欢迎健康志愿者
40 至 75 岁 · 所有性别 · 更新于 2026年11月4日 · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Gabrail Cancer Center, Canton
- Miami Valley Hospital South, Centerville
- Oncology Hematology Care, Cincinnati
- 以及另外 2 项
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年11月3日 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Case Western Reserve University, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年11月2日 · NCT05564390Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Cincinnati Medical Center (University Hospital), Cincinnati
- The Ohio State University Comprehensive Cancer Center (OSUCCC), Cleveland
招募中3 期
18 至 75 岁 · 所有性别 · 更新于 2026年10月30日 · NCT05429632Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Cleveland Clinic Mercy Hospital, Canton
- University Hospitals Seidman Cancer Center, Cleveland
- Tri-County Hematology & Oncology Associates, Inc., Massillon
招募中观察性研究
18 岁及以上 · 所有性别 · 更新于 2026年10月30日 · NCT05974150Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
招募中观察性研究
0 至 38 岁 · 所有性别 · 更新于 2026年10月29日 · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Case Western Reserve University, Cleveland
招募中2 期
18 至 59 岁 · 所有性别 · 更新于 2026年10月28日 · NCT05554393A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- The Ohio Sate University, Columbus
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月23日 · NCT06969430A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
招募中1 期
21 岁及以下 · 所有性别 · 更新于 2026年10月23日 · NCT07012044Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
招募中1 期
1 至 30 岁 · 所有性别 · 更新于 2026年10月22日 · NCT06177067Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月20日 · NCT06533761Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Cleveland Clinic Cancer Center, Cleveland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月20日 · NCT06543381Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Ohio State University, The James Comprehensive Cancer, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月16日 · NCT06846606A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
招募中1/2 期
30 Days · 所有性别 · 更新于 2026年10月9日 · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Cincinnati, Cincinnati
- OhioHealth Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
招募中观察性研究
0 岁及以上 · 所有性别 · 更新于 2026年10月9日 · NCT07154823Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
- Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland
- University Hospitals Seidman Cancer, Case Comprehensive Cancer Center, Cleveland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年10月8日 · NCT06129734A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
招募中2/3 期
18 岁及以上 · 所有性别 · 更新于 2026年10月6日 · NCT04256317Ziftomenib Maintenance Post Allo-HCT
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年10月6日 · NCT06440135Ivosidenib as Post-HSCT Maintenance for AML
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
招募中2 期
18 至 75 岁 · 所有性别 · 更新于 2026年10月5日 · NCT06707493Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年9月24日 · NCT03874052A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 以及另外 4 项
招募中3 期
6 Months – 21 Years · 所有性别 · 更新于 2026年9月17日 · NCT04293562Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月15日 · NCT06904482Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland
招募中1/2 期
18 岁及以上 · 所有性别 · 更新于 2026年9月14日 · NCT03471260Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
- Ohio State University Comprehensive Cancer Center, Columbus
招募中1/2 期
18 至 75 岁 · 所有性别 · 更新于 2026年9月9日 · NCT04049539Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Rainbow Babies and Childrens Hospital, Cleveland
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
招募中3 期
1 至 25 岁 · 所有性别 · 更新于 2026年9月4日 · NCT07022678Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Cincinnati OH-CINCY, Cincinnati
- US-Colombus OH-OSU, Columbus
招募中3 期
18 岁及以上 · 所有性别 · 更新于 2026年9月2日 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 以及另外 3 项
招募中1/2 期
22 岁及以下 · 所有性别 · 更新于 2026年8月25日 · NCT04726241A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
招募中1 期
18 至 75 岁 · 所有性别 · 更新于 2026年8月25日 · NCT05886049Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年8月20日 · NCT06001788L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University Hospitals Cleveland Medical Center, Cleveland
招募中2/3 期
18 至 80 岁 · 所有性别 · 更新于 2026年8月5日 · NCT06788756A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Childrens Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital, Cincinnati
- University Hospitals Case Medical Center, Cleveland
- 以及另外 3 项
招募中观察性研究
所有年龄段 · 所有性别 · 更新于 2026年7月6日 · NCT01351545IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
- Ohio State University Comprehensive Cancer Center, Columbus
招募中2 期
18 岁及以上 · 所有性别 · 更新于 2026年6月23日 · NCT05401097A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
- Case Western Reserve University, Cleveland
招募中1 期
18 岁及以上 · 所有性别 · 更新于 2026年6月12日 · NCT05834244数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。